Autism Spectrum Disorders: Clinical Trials

4 trials for Autism Spectrum Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting, 1 terminated, 1 withdrawn. 4 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 34Completed 1, Recruiting 1, Terminated 1, Withdrawn 1
Phase 21Withdrawn 1

Follow Autism Spectrum Disorders: new trials by email Literature Review of Autism Spectrum Disorders trials Research Report on Autism Spectrum Disorders

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th
Arbaclofen, Placebo - Autism Spectrum Disorders
Phase 3RecruitingHospital General Universitario Gregorio Marañon1032025-11-202026-06-17
Cortical Metrics in Intervention Trials With Autism Spectrum Disorders
Dextromethophan - Autism Spectrum Disorders
Phase 2 / Phase 3WithdrawnDuke University2015-08-012016-08-25
Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
STX209 (arbaclofen) - Autism Spectrum Disorders
Phase 3TerminatedSeaside Therapeutics, Inc.1652011-11-012013-07-31
Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
Placebo, Mirtazapine - Autism Spectrum Disorders
Phase 3CompletedMassachusetts General Hospital302010-08-012018-11-07

Narrower conditions

Autism Spectrum Disorder (4)  ·  Autistic Disorder (3)  ·  Asperger Syndrome (1)  ·  Child Development Disorders, Pervasive (1)

Broader conditions

Mental Disorders (4)  ·  Neurodevelopmental Disorders (4)  ·  Child Development Disorders, Pervasive (3)

Interventions

Mirtazapine (1)  ·  Sugars (1)  ·  arbaclofen placarbil (1)

Sponsors

Duke University (1)  ·  Hospital General Universitario Gregorio Marañon (1)  ·  Massachusetts General Hospital (1)  ·  Seaside Therapeutics, Inc. (1)

Countries

United States (3)  ·  France (1)  ·  Spain (1)

Top investigators

Christopher J. McDougle, M.D. (1)  ·  Linmarie Sikich, MD (1)  ·  Paul Wang, M.D. (1)

Results publications

PMID 35241779

NIH funding

2023 (1)